Cann Group Stock

Cann Group P/E

The (Price Earnings Ratio) is an important metric for stock valuation. It is calculated by dividing the current share price by the earnings per share. The P/E indicates how many years it would take to recoup the current share price through the expected earnings per share. A low P/E may indicate that a stock is undervalued, while a high P/E may suggest an overvalued stock. However, the P/E alone should not be considered the sole basis for an investment decision, as other factors must also be taken into account. of Cann Group (CAN.AX) as of Jul 30, 2026 is -0.50. In the previous year, (Price Earnings Ratio) is an important metric for stock valuation. It is calculated by dividing the current share price by the earnings per share. The P/E indicates how many years it would take to recoup the current share price through the expected earnings per share. A low P/E may indicate that a stock is undervalued, while a high P/E may suggest an overvalued stock. However, the P/E alone should not be considered the sole basis for an investment decision, as other factors must also be taken into account. was -0.22 — a change of 129.32% (lower).

P/E

-0.50

YoY

129.32%

Last updated:

As of Jul 30, 2026, Cann Group's P/E ratio was -0.50, a 129.32% change from the -0.22 P/E ratio recorded in the previous year.

The Cann Group P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/E
Date
P/E
Jan 1, 2018
-32.64 base
Jan 1, 2019
-7.99 base
Jan 1, 2020
-4.95 base
Jan 1, 2021
-2.97 base
Jan 1, 2022
-2.74 base
Jan 1, 2023
-1.13 base
Jan 1, 2024
-0.35 base
Jan 1, 2025
-0.21 base
YEARP/E
2025 -0.21
2024 -0.35
2023 -1.13
2022 -2.74
2021 -2.97
2020 -4.95
2019 -7.99
2018 -32.64
2017 -68.89
2016 -
2015 -
Access this data via the Eulerpool API

Cann Group Valuation

Details

Historical Valuation Multiples

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Cann Group's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Cann Group's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Cann Group's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Cann Group grows earnings faster than its peers.

Cann Group Stock analysis

What does Cann Group do? Cann Group Ltd is an Australian company specializing in the production and marketing of medical cannabis. The company was founded in 2013 and is headquartered in Melbourne. The company's history began with the founding of an independent consulting firm called AusCann Group Holdings Ltd in 2014. This firm was created to inform Australian and international investors about the opportunities and possibilities in the Australian cannabis market. In 2016, a cooperation agreement was signed between AusCann and Cann Group Ltd to advance the cultivation and production of medical cannabis products in Australia. Since then, Cann Group has continuously invested in the development and growth of the Australian medical cannabis market. The company has obtained a Good Manufacturing Practices (GMP) compliance license to ensure that all products meet the highest quality and safety standards. This includes collaborating with research institutions and state health authorities to investigate the efficacy and safety of medications. Cann Group's various business areas include the production of medical cannabis, research, product development, and marketing. The company operates a cannabis cultivation facility in Cochranes Hill, Victoria, covering an area of 20 hectares. The cultivation of cannabis is carried out under controlled conditions to ensure that all products are of the highest quality and purity. The cultivated cannabis is then used to manufacture medical products such as oils, tinctures, capsules, and sprays. Cann Group also collaborates closely with research institutions and academic institutions to study the safety and efficacy of medical cannabis. The company has partnerships with the University of Melbourne, Queensland University of Technology, and Swinburne University of Technology for research on the mechanisms of cannabis, application research, and studies on the clinical efficacy of cannabis. The business model of Cann Group is based on the sale of medical cannabis products to pharmacies and medical facilities in Australia and worldwide. The company, through its license, is one of the few companies capable of producing and exporting medical cannabis for the Australian market. In addition to exporting cannabis products to Germany, New Zealand, the UK, and other countries, the sale of cannabis products to the Australian market is the largest market for Cann Group. The company offers a variety of medical cannabis products specifically developed for various medical conditions. These include products for anxiety, nausea and vomiting, pain, seizures, and many other diseases. There are also products for palliative care, which help alleviate pain and suffering in the final stages. Overall, Cann Group Ltd has played a pioneering role in the development of the Australian medical cannabis market in recent years. The company specializes in the production of medical cannabis products that meet the highest quality standards and strict regulatory requirements. The company is committed to improving the therapeutic approach to diseases and enhancing the quality of life for patients. Cann Group is one of the most popular companies on Eulerpool.

P/E Details

Deciphering Cann Group's P/E Ratio

The Price to Earnings (P/E) Ratio of Cann Group is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Cann Group's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Cann Group is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Cann Group’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Cann Group stock

(Price Earnings Ratio) is an important metric for stock valuation. It is calculated by dividing the current share price by the earnings per share. The P/E indicates how many years it would take to recoup the current share price through the expected earnings per share. A low P/E may indicate that a stock is undervalued, while a high P/E may suggest an overvalued stock. However, the P/E alone should not be considered the sole basis for an investment decision, as other factors must also be taken into account. of Cann Group is -0.50 in 2026.

The P/E ratio in evaluating a stock.

The price-earnings ratio (P/E ratio) is an important financial ratio that is often used by investors to assess the attractiveness of a stock. It is an indicator of a company's earnings and valuation, and provides an indication of whether a stock is overvalued or undervalued. It is also used as an indicator of whether a stock is "expensive" or "cheap".

History of P/E ratio

The P/E ratio was first used in 1881 by the famous financial scientist Benjamin Graham. He developed the P/E ratio as a means to evaluate whether a stock is trading at a "good" or "bad" price. Since then, the P/E ratio has had a long history in the financial world, particularly among investors who are looking for a way to evaluate stocks in an informed manner.

Calculation of the P/E ratio

The P/E ratio is calculated by dividing the current stock price by the earnings per share. A simple formula for calculating the P/E ratio is as follows:

P/E ratio = Stock price / Earnings per share

Example: If a stock is traded at the current price of $10 and the earnings per share is $1, the P/E ratio would be 10 ($10 / $1 = 10).

Application of the P/E ratio

Investors use the P/E ratio to assess the attractiveness of a stock. A high P/E ratio can indicate that a stock is overvalued, while a low P/E ratio means that a stock is undervalued. Investors can then decide whether to buy, sell, or hold a stock based on this information. Another reason why investors use the P/E ratio is to check how stocks perform compared to other stocks or the market as a whole. If a stock's P/E ratio is higher than the overall market's P/E ratio, this may mean that the stock is overvalued, and investors can decide whether to sell or hold the stock. Investors usually also use the P/E ratio to compare stocks over time. If a stock has a P/E ratio of 10 and a year later has a P/E ratio of 20, this may mean that the stock is overvalued. Investors can then decide whether to hold or sell the stock.

Advantages and Disadvantages of using the P/E ratio

BenefitsThe P/E ratio is a useful tool to assess the attractiveness of a stock and to evaluate how a stock is performing compared to the market. It is a simple tool that can assist investors in deciding whether to buy, sell, or hold a stock.

DisadvantagesThe P/E ratio is a simple tool that does not provide any information about the future performance of a stock. It can be difficult to predict the future performance of a stock, and sometimes the P/E ratio can give a false picture of a stock. Therefore, investors must be cautious when relying on the P/E ratio.

In addition, the P/E ratio can vary depending on the industry, which makes comparability difficult. For example, a stock in a certain industry may have a low P/E ratio, while another stock in a different industry may have a higher P/E ratio. Therefore, investors must be cautious when relying on the P/E ratio.

Conclusion

The P/E ratio is a useful tool that can assist investors in assessing the attractiveness and value of a stock. It can also be used to check how a stock is performing in comparison to the market. However, it is important to note that it is a simple tool that does not make any statement about the future performance of a stock, and investors must be cautious when relying on the P/E ratio.

Access this data via the Eulerpool API

Valuation — Cann Group

All Key Metrics — Cann Group